RCS - Verici Dx PLC - Lease signed for laboratory

Verici DxAnnouncement

29/04/2021 07:05

RNS Number : 9877W
  
Verici Dx PLC
  
29 April 2021
  
 

Verici Dx plc
("Verici Dx" or the "Company") 
 
Lease signed for laboratory as part of CLIA approval acceleration strategy
 
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has signed the lease for the premises intended to be the CLIA1-certified laboratory, situated at the Innovation Park2 in Franklin, Tennessee, US, which is within the Palmetto region for CMS Medicare governance. Palmetto GBA, LLC is one of the largest Medicare administration contractors in the US.
 
In January 2021, the Company appointed David Schultenover to accelerate the CLIA approval process to enable faster commercial launch of Verici Dx's lead products, ClaravaTM and TutevaTM and setting up these premises is the first step in that accelerated pathway. The Company requires a CLIA-certified laboratory to be able to offer their diagnostic products to clinicians as a laboratory developed test (LDT) and approvals are expected by the end of the year. The Center for Medicare and Medicaid Services (CMS) regulates laboratory testing in the US through the CLIA regime, which requires all clinical laboratories to be certified before they can accept human samples for diagnostic testing.
 
David Schultenover, VP Quality and Regulatory Affairs at Verici Dx, commented: "I joined the Company in January this year to help expedite the CLIA approval strategy and signing the lease to this space marks the first step towards achieving these CLIA approvals necessary for commercial launch of the Company's leading products, ClaravaTM and TutevaTM. Innovation Park is an ideal location for the Company to establish operations and we are delighted with the quality of the premises which are well suited for our needs." 
 
1 - CLIA - Clinical Laboratory Improvement Amendments
2 - Innovation Park is a 10 acre campus for growing start-ups or established companies. More information can be found here: http://www.theinnovationpark.com/#campus 
 
Enquiries:
 



Verici Dx


www.vericidx.com




Sara Barrington, CEO 


Via Walbrook PR




Julian Baines, Chairman


 








 




N+1 Singer (Nominated Adviser & Broker)


Tel: 020 7496 3000




Aubrey Powell / Justin McKeegan / Tom Salvesen 


 








 




Walbrook PR Limited


Tel: 020 7933 8780 or vericidx@walbrookpr.com




Paul McManus / Sam Allen


Mob: 07980 541 893 / 077502 558 258



 
 
 
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
 
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAUWSKRAKUSUAR